TNKS small‐molecule inhibitors block Wnt/β‐catenin signaling by stabilizing AXIN1 and AXIN2, and have therefore been investigated for targeted treatment of colorectal cancer [14, 16, 17]. This evidence concerns the gene AXIN2 and colorectal cancer.